AAM
VERV

Alpine Associates Management’s Verve Therapeutics VERV Stock Holding History

Alpine Associates Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,738,212
Closed -$30.8M – 96
2025
Q2 		$30.8M Buy
+2,738,212
New +$15.6M 1.64% 17

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Alpine Associates Management's VERV Position: Q3 2025 in Review

Alpine Associates Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 2,738,212 shares — an estimated $30.8M sold.

Alpine Associates Management first reported a position in VERV in Q2 2025 and held it in 1 quarter. The position peaked at $30.8M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Alpine Associates Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Alpine Associates Management sold 2,738,212 Verve Therapeutics shares in Q3 2025, an estimated $30.8M.
  • Alpine Associates Management first reported a position in Verve Therapeutics in Q2 2025 and held it in 1 quarter.
  • Alpine Associates Management's Verve Therapeutics position peaked at $30.8M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Alpine Associates Management's 13F filing for Q3 2025, filed 6 Nov 2025.